A Randomized Open-Label, Multi-Center Pivotal Study of ANG1005 Compared with Physician's Best Choice in HER2-Negative Breast Cancer Patients with Newly Diagnosed Leptomeningeal Carcinomatosis and Previously Treated Brain Metastases (ANGLeD)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Angiochem Inc.
Start Date
October 2, 2019
End Date
October 10, 2024
Administered By
Duke Cancer Institute
Awarded By
Angiochem Inc.
Start Date
October 2, 2019
End Date
October 10, 2024